Clinical Trials Data Monitoring Committees
Patient dosing continues in clinical trial of novel gene therapy for Wilson’s disease
A European clinical stage biotech company announced dosing of the first patient in cohort 2 of its ongoing phase 1/2 GATEWAY clinical trial of lead candidate VTX-801 to treat Wilson’s disease.
Phase 2/3 trial of Alzheimer’s therapy permitted to continue by monitoring board
Annovis Bio has been permitted by the Data and Safety Monitoring Board to continue its phase 2/3 trial of buntanetap, an oral protein inhibitor for moderate to mild Alzheimer’s disease, according to a company release.
FDA places partial clinical hold on initiation of new patients in evobrutinib study
Merck KGaA announced the FDA has paused the initiation of new patients on evobrutinib for relapsing-remitting MS, as well as those with less than 70 days exposure to the treatment in the United States.
Enrollment in MI trials declines
Enrollment in clinical trials of patients treated for MI has decreased over time, according to findings published in the American Heart Journal.